Yeap - Google Patents
THE USE OF BISPHOSPHONATES IN OSTEOPOROSIS: A REV| E. VVYeap
View PDF- Document ID
- 4594631426309868327
- Author
- Yeap S
External Links
Snippet
Bisphosphonates are synthetic anafogues of pyrophosphate. Their main pharmacological effect is to inhibit bone resorption by a variety of mechanisms, not all of which are clearly understood. The activity of the bisphosphonates varies depending on the compound. In …
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization 0 title abstract description 44
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Watts | Treatment of osteoporosis with bisphosphonates | |
| Licata | Bisphosphonate therapy | |
| US5891863A (en) | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices | |
| Gatti et al. | New bisphosphonates in the treatment of bone diseases | |
| Sparidans et al. | Bisphosphonates in bone diseases | |
| RU2453316C2 (en) | Prolonged slow release pharmaceutical composition containing water suspension of bisphosphonate | |
| Rodan et al. | Preclinical pharmacology of alendronate | |
| EP0675723A1 (en) | Bisphosphonate/estrogen therapy for treating and preventing bone loss | |
| Brown et al. | Developments in the therapeutic applications of bisphosphonates | |
| Rossini et al. | Intramuscular clodronate therapy in postmenopausal osteoporosis | |
| Giannini et al. | Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss | |
| Selby | Alendronate treatment for osteoporosis: a review of the clinical evidence | |
| US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
| AU701258B2 (en) | Bone mass anabolic composition comprising olpadronate | |
| Yeap | THE USE OF BISPHOSPHONATES IN OSTEOPOROSIS: A REV| E. VV | |
| Yeap | The Use of Bisphosphonates In Osteoporosis: A Review | |
| Ghinoi et al. | Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders | |
| Bauss | Ibandronate in malignant bone diseases and osteoporosis–Preclinical results | |
| Fleisch | Bisphosphonates | |
| Bonjour et al. | Treatment of hypercalcaemia of malignancy with clodronate | |
| Doga et al. | Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis | |
| Compston | Fortnightly Review | |
| MXPA96004968A (en) | Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis |